Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or
Faster, Cleaner, Better.

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
19.90 x 5 20.18 x 18
Pre-market by (Cboe BZX)
19.78 -0.38 (-1.88%) 06/13/25 [NASDAQ]
19.90 x 5 20.18 x 18
Pre-market 20.03 +0.25 (+1.26%) 08:53 ET
Quote Overview for Mon, Jun 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
20.11
Day High
20.11
Open 20.11
Previous Close 19.78 19.78
Volume 6,047 6,047
Avg Vol 4,929,442 4,929,442
Stochastic %K 36.05% 36.05%
Weighted Alpha +2.28 +2.28
5-Day Change -1.45 (-6.73%) -1.45 (-6.73%)
52-Week Range 6.78 - 36.91 6.78 - 36.91
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,689,934
  • Shares Outstanding, K 742,666
  • Annual Sales, $ 0 K
  • Annual Income, $ -221,320 K
  • EBIT $ -250 M
  • EBITDA $ -250 M
  • 60-Month Beta -1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 43.48

Options Overview Details

View History
  • Implied Volatility 77.39% ( +4.75%)
  • Historical Volatility 133.30%
  • IV Percentile 5%
  • IV Rank 7.19%
  • IV High 185.04% on 08/12/24
  • IV Low 69.06% on 06/10/25
  • Put/Call Vol Ratio 0.77
  • Today's Volume 7,684
  • Volume Avg (30-Day) 8,753
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 141,008
  • Open Int (30-Day) 113,345

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.10
  • Number of Estimates 5
  • High Estimate -0.09
  • Low Estimate -0.10
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.03 +25.45%
on 06/02/25
Period Open: 23.87
27.09 -25.77%
on 05/29/25
-3.76 (-15.75%)
since 05/16/25
3-Month
15.55 +29.32%
on 04/07/25
Period Open: 20.79
36.91 -45.52%
on 04/24/25
-0.68 (-3.27%)
since 03/14/25
52-Week
6.78 +196.61%
on 07/03/24
Period Open: 8.39
36.91 -45.52%
on 04/24/25
+11.72 (+139.69%)
since 06/14/24

Most Recent Stories

More News
Why Summit Therapeutics Stock Tanked Today

NFLX : 1,216.99 (+0.40%)
NVDA : 143.43 (+1.03%)
$SPX : 5,976.97 (-1.13%)
SMMT : 20.11 (+1.67%)
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone accounts...

MRK : 81.23 (-0.59%)
SMMT : 20.11 (+1.67%)
MRNA : 26.76 (+0.34%)
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below. The...

NVO : 78.04 (-2.24%)
SMMT : 20.11 (+1.67%)
LLY : 824.97 (+0.68%)
PFE : 24.58 (+0.16%)
2 Soaring Stocks Wth More Upside Potential

SMMT : 20.11 (+1.67%)
AXSM : 104.10 (-2.02%)
3 No-Brainer Healthcare Stocks to Buy in June

SMMT : 20.11 (+1.67%)
VRTX : 455.45 (-1.00%)
AMGN : 296.50 (+0.43%)
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?

SMMT : 20.11 (+1.67%)
Why Summit Therapeutics Plunged Today

SMMT : 20.11 (+1.67%)
AKESF : 11.2250 (-7.69%)
JEF : 52.20 (-2.59%)
MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?

Merck’s MRK shares have lost 21.3% so far this year compared with a decrease of 4.5% for the industry. The stock has also underperformed the sector and the S&P 500 Index, as seen in the chart below....

MRK : 81.23 (-0.59%)
SMMT : 20.11 (+1.67%)
MRNA : 26.76 (+0.34%)
3 High-Flying Stocks That Could Soar Even More

SMMT : 20.11 (+1.67%)
ALNY : 307.99 (+1.09%)
AXSM : 104.10 (-2.02%)
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

IOVA : 2.25 (+0.45%)
ONC : 269.63 (-2.50%)
SMMT : 20.11 (+1.67%)
MRK : 81.23 (-0.59%)
VRTX : 455.45 (-1.00%)
PFE : 24.58 (+0.16%)
BMY : 49.86 (+0.22%)
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio.3SBio is...

MRK : 81.23 (-0.59%)
SMMT : 20.11 (+1.67%)
PFE : 24.58 (+0.16%)
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money

MSFT : 476.70 (+0.37%)
GOOGL : 175.75 (+0.62%)
NVDA : 143.43 (+1.03%)
GOOG : 177.04 (+0.66%)
SKM : 23.62 (+7.66%)
SMMT : 20.11 (+1.67%)
MRK : 81.23 (-0.59%)
APLD : 11.42 (+2.15%)
IONQ : 37.43 (-1.08%)
GD : 283.00 (+1.10%)
AMZN : 213.85 (+0.83%)
Can Summit Therapeutics Stock Double Your Money?

Summit Therapeutics (NASDAQ: SMMT) has more than just a potential blockbuster cancer drug in its portfolio. Ivonescimab could be one of the best drugs to ever hit the market. This has investors excited...

SMMT : 20.11 (+1.67%)
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil

Summit Therapeutics SMMT reported first-quarter 2025 loss per share of 9 cents, narrower than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago period, the company incurred a loss of...

MRK : 81.23 (-0.59%)
SMMT : 20.11 (+1.67%)
PFE : 24.58 (+0.16%)
This Soaring Stock Just Delivered More Good News. Time to Buy?

It's hard to find a biotech company that has performed better than Summit Therapeutics (NASDAQ: SMMT) in the past year. The stock is up by a whopping 512%, and it's no secret why.

SMMT : 20.11 (+1.67%)
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?

Merck MRK reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings of $2.22 per share rose 12% year over year, excluding foreign exchange impact....

MRK : 81.23 (-0.59%)
SMMT : 20.11 (+1.67%)
MRNA : 26.76 (+0.34%)
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (NASDAQ: SMMT) and BioNTech...

SMMT : 20.11 (+1.67%)
AKESF : 11.2250 (-7.69%)
BNTX : 108.80 (+2.09%)
Why Summit Therapeutics Rocketed Double-Digits Today

Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET.

BGNE : 184.71 (+0.49%)
SMMT : 20.11 (+1.67%)
AKESF : 11.2250 (-7.69%)
This Company's Co-CEOs Just Bought More Shares. Should You?

Nobody has more information about a company than its insiders, especially its executive management team. That's why when one of them buys more shares, it sometimes gives individual investors insights into...

SMMT : 20.11 (+1.67%)
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.

SMMT : 20.11 (+1.67%)
RXRX : 5.05 (+2.64%)
PTN : 0.0941 (-44.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 20.97
2nd Resistance Point 20.50
1st Resistance Point 20.14
Last Price 20.11
1st Support Level 19.31
2nd Support Level 18.84
3rd Support Level 18.48

See More

52-Week High 36.91
Fibonacci 61.8% 25.40
Fibonacci 50% 21.84
Last Price 20.11
Fibonacci 38.2% 18.29
52-Week Low 6.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Market Leaders Revealed: How to Spot the S&P 500's Top Performers Before the Crowd

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.